Immix Biopharma, Inc. Q2 2026: Net loss $(11.56) M, EPS $(0.18) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Immix Biopharma reported a Q2 2026 net loss of $11.56M and diluted EPS of $(0.18), widening from the prior year's $6.62M loss, with no product revenue as it remains clinical-stage. The company completed enrollment in NEXICART-2, showing high response rates for NXC-201, which holds FDA Breakthrough Therapy and RMAT designations. Increased R&D spending supports Phase 3 efforts, funded by equity offerings and CIRM grants.
Immix Biopharma, Inc. reported a larger consolidated net loss for the quarter ended June 30, 2026, with net income of $(11.56) M and diluted EPS of $(0.18); the company remains clinical-stage with no product revenue for the period.
Financial Highlights
- Net income: $(11.56) M for the quarter ended June 30, 2026, versus $(6.62) M in the year-ago quarter.
- Diluted EPS: $(0.18) for the quarter ended June 30, 2026, versus $(0.22) in the year-ago quarter.
- Revenue: No product sales; company is clinical-stage and reports no revenue for the quarter.
Business Highlights
- Clinical progress: Enrollment complete in NEXICART-2 (45 patients); Phase 1b/2 data show high complete response rates (95% of evaluable patients) and rapid responses.
- Regulatory designations: NXC-201 received FDA Breakthrough Therapy, RMAT and orphan drug designations in the U.S. and EU, supporting an expedited development path.
- R&D activity: Increased clinical R&D spending and higher CRO/site costs to support expanded trial operations and planned Phase 3 efforts.
- Funding: Multiple equity offerings and CIRM grant reimbursements (~$8M) have funded trial progression and extended cash runway.
- Safety profile: Favorable tolerability observed with no neurotoxicity and predominantly low-grade cytokine release syndrome, supporting broader development plans.
Original SEC Filing: Immix Biopharma, Inc. [ IMMX ] - 10-Q - Aug. 07, 2026